Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,870 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Molecule based diagnosis].
Akaza H, Ichikawa T, Tsuruo T, Shimada Y, Moriwaki H, Mori M, Noguchi S, Nakamura S, Saijo N, Sone S, Isonishi S, Ohashi Y, Hinotsu S, von Euler M, Blackedge G. Akaza H, et al. Among authors: nakamura s. Gan To Kagaku Ryoho. 2004 Jan;31(1):125-33. Gan To Kagaku Ryoho. 2004. PMID: 14750337 Review. Japanese.
[Post launch studies].
Akaza H, Ohashi Y, Shimada Y, Ikeda T, Saijo N, Isonishi S, Hirao Y, Tsuruo T, Tsukagoshi S, Sone S, Nakamura S, Kato M, Mikami O, von Euler M, Blackledge G, Milsted B, Vose B. Akaza H, et al. Among authors: nakamura s. Gan To Kagaku Ryoho. 2002 Nov;29(11):2037-48. Gan To Kagaku Ryoho. 2002. PMID: 12465411 Japanese.
[Anti angiogenesis].
Akaza H, Nakagawa M, Tsuruo T, Saijo N, Sone S, Yamamoto N, Kakeji Y, Nakamura S, Kurebayashi J, Isonishi S, Ohashi Y, Blackledge G, Carmichael J. Akaza H, et al. Among authors: nakamura s. Gan To Kagaku Ryoho. 2004 Apr;31(4):647-55. Gan To Kagaku Ryoho. 2004. PMID: 15114718 Review. Japanese.
[Future directions of anticancer drug development in Japan].
Akaza H, Kawai K, Tsuruo T, Tsukagoshi S, Aiba K, Shimada Y, Kakeji Y, Ishikawa H, Ikeda T, Nakamura S, Tamura T, Yamamoto N, Isonishi S, Hinotsu S, Hirose M, Katsura J. Akaza H, et al. Among authors: nakamura s. Gan To Kagaku Ryoho. 2008 Feb;35(2):351-60. Gan To Kagaku Ryoho. 2008. PMID: 18281781 Japanese.
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Tada T, et al. Among authors: nakamura s. Aliment Pharmacol Ther. 2024 May 8. doi: 10.1111/apt.18037. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 38716823
10,870 results
You have reached the last available page of results. Please see the User Guide for more information.